文献速递冠心病

ABSORB III 试验五年随访:依维莫司生物可吸收支架完全吸收前后的临床结局

Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
PubMed 文献 · Circulation · 2019-09-25

ABSORB III 试验比较依维莫司生物可吸收支架(BVS)与钴铬依维莫司洗脱支架,1 年靶病变失败率 BVS 非劣于金属支架。但 1 至 3 年及累积 3 年 BVS 不良事件(尤其靶血管心肌梗死和支架血栓)增加。五年随访累积事件率 BVS 仍较高,但 3 至 5 年相对风险较 0 至 3 年下降,超额风险在 3 年支架完全吸收时结束。

要点

  • BVS 累积 5 年靶病变失败、靶血管心肌梗死和支架血栓率高于依维莫司洗脱支架。
  • 3 至 5 年 BVS 相对风险较 0 至 3 年下降,靶病变失败 HR 0.83 vs 1.35(Pint=0.052)。
  • 支架血栓 3 至 5 年 HR 0.26 vs 0 至 3 年 3.23(Pint=0.056),超额风险止于 3 年。

核心结论

  • ABSORB III 试验五年累积不良事件率 BVS 高于依维莫司洗脱支架。
  • BVS 超额风险期在 3 年结束,与支架完全吸收时间吻合。

研究设计与样本

  • ABSORB III 试验按随机器械(意向治疗)分析累积至 5 年及 3 至 5 年临床结局。

主要发现

  • BVS 累积 5 年靶病变失败、靶血管心肌梗死和支架血栓率增加。
  • 3 至 5 年 BVS 相对风险较 0 至 3 年下降,靶病变失败 HR 0.83(95%CI 0.55-1.24)vs 1.35(95%CI 1.02-1.78),Pint=0.052。
  • 3 至 5 年支架血栓 HR 0.26(95%CI 0.02-2.87)vs 0 至 3 年 3.23(95%CI 1.25-8.30),Pint=0.056。

临床怎么用

  • BVS 植入后需关注 3 年内靶血管心肌梗死和支架血栓风险。
  • 3 年后 BVS 相对风险下降,但累积 5 年事件率仍高于依维莫司洗脱支架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support similar to those of metallic drug-eluting stents, followed by complete resorption in ≈3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization) at 1 year with BVS compared with cobalt chromium everolimus-eluting stents. Between 1 and 3 years and cumulative to 3 years, adverse event rates (particularly target vessel myocardial infarction and scaffold thrombosis) were increased after BVS. We sought to assess clinical outcomes after BVS through 5 years, including beyond the 3-year time point of complete scaffold resorption. METHODS: Clinical outcomes from ABSORB III were analyzed by randomized device (intention to treat) cumulative to 5 years and between 3 and 5 years. RESULTS: Rates of target lesion failure, target vessel myocardial infarction, and scaffold thrombosis were increased through the 5-year follow-up with BVS compared with everolimus-eluting stents. However, between 3 and 5 years, reductions in the relative hazards of the BVS compared with everolimus-eluting stents were observed, particularly for target lesion failure (hazard ratio, 0.83 [95% CI, 0.55-1.24] versus 1.35 [95% CI, 1.02-1.78]; Pint=0.052) and scaffold thrombosis (hazard ratio, 0.26 [95% CI, 0.02-2.87] versus 3.23 [95% CI, 1.25-8.30]; Pint=0.056) compared with the 0- to 3-year time period. CONCLUSIONS: In the ABSORB III trial, cumulative 5-year adverse event rates were increased after BVS compared with everolimus-eluting stents. However, the period of excess risk for BVS ended at 3 years, coincident with complete scaffold resorption. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT01751906.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kereiakes DJ, Ellis SG, Metzger DC, et al. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial. Circulation. 2019. PMID: 31553222. doi:10.1161/CIRCULATIONAHA.119.042584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。